Promega Corporation v. Applied Biosystems, LLC, Life Technologies Corporation, and California Institute of Technology

June 20, 2013

Judge Richard A. Posner ruled in favor of our client, Promega Corporation, in a suit that it initiated against one of its competitors. In an opinion dated June 12, 2013 from the U.S. District Court for the Northern District of Illinois, Judge Posner ruled that certain claims of U.S. Patent No. RE43,096, asserted against Promega, are invalid. Promega prevailed in its arguments that the claims of the ’096 patent were invalid due to the breadth of the claim constructions that Defendants sought and obtained. Certain asserted claims were invalid for lack of written description support. While the patent describes an improvement to DNA sequencing, the breadth of the claims encompassed technologies that Caltech did not invent, including the PCR-based methods on which Promega’s accused products are based. The asserted claims were additionally invalid as anticipated or obvious in view of the prior art, including a prior art patent to Caltech, which expired years ago. Judge Posner also found certain claims invalid for obviousness type double patenting.

Cyrus A. Morton

Partner

Chair, Patent Office Trials Group

Sharon E. Roberg-Perez, Ph.D.

Partner

Co-Chair, Diversity Committee

Denise S. Rahne

Partner

Co-Chair, Wealth Planning, Administration, and Disputes

Related Publications

Winter 2021
Pro Bono Publico–For The Public Good
Tim Billion, Lindsey Hanson - The Robins Kaplan Spotlight, Vol. 5, No. 4
Winter 2021
The Case for Charitable Giving
Matthew Frerichs, Sarah Khoury - The Robins Kaplan Spotlight, Vol. 5, No. 4
Winter 2021
The Fictional Wealth Disputes That We Took In and Learned From in 2020
Ena Kovacevic - The Robins Kaplan Spotlight, Vol. 5, No. 4
Fourth Quarter
ANDA Approvals
GENERICally Speaking Winter 2021
Back to Top